Taysha Gene Therapies (NASDAQ:TSHA) Posts Quarterly Earnings Results, Beats Estimates By $0.03 EPS

Taysha Gene Therapies (NASDAQ:TSHA) released its earnings results on Thursday. The company reported ($0.08) EPS for the quarter, beating analysts’ consensus estimates of ($0.11) by $0.03, FiscalAI reports. Taysha Gene Therapies had a negative return on equity of 67.26% and a negative net margin of 1,144.97%.The company had revenue of $5.49 million during the quarter, compared to analysts’ expectations of $1.89 million.

Taysha Gene Therapies Price Performance

Shares of TSHA opened at $4.45 on Thursday. The company has a market capitalization of $1.22 billion, a P/E ratio of -13.48 and a beta of 1.02. The company has a quick ratio of 10.48, a current ratio of 10.48 and a debt-to-equity ratio of 0.23. The firm has a 50 day moving average of $4.66 and a 200 day moving average of $4.53. Taysha Gene Therapies has a twelve month low of $1.05 and a twelve month high of $6.02.

Insider Activity at Taysha Gene Therapies

In other Taysha Gene Therapies news, insider Sukumar Nagendran sold 200,000 shares of the stock in a transaction on Monday, January 12th. The stock was sold at an average price of $4.71, for a total transaction of $942,000.00. Following the sale, the insider directly owned 1,006,439 shares in the company, valued at approximately $4,740,327.69. This trade represents a 16.58% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Sean P. Nolan sold 136,789 shares of Taysha Gene Therapies stock in a transaction on Friday, January 23rd. The stock was sold at an average price of $4.75, for a total value of $649,747.75. Following the completion of the sale, the chief executive officer directly owned 2,949,569 shares of the company’s stock, valued at approximately $14,010,452.75. The trade was a 4.43% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last three months, insiders have sold 598,623 shares of company stock valued at $2,822,188. 3.78% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Taysha Gene Therapies

Institutional investors have recently modified their holdings of the business. Invesco Ltd. increased its holdings in Taysha Gene Therapies by 376.3% in the 4th quarter. Invesco Ltd. now owns 1,332,780 shares of the company’s stock worth $7,330,000 after buying an additional 1,052,987 shares in the last quarter. Oracle Investment Management Inc. bought a new position in Taysha Gene Therapies during the 4th quarter valued at about $1,458,000. Voloridge Investment Management LLC bought a new position in Taysha Gene Therapies during the 4th quarter valued at about $301,000. Vestal Point Capital LP boosted its holdings in shares of Taysha Gene Therapies by 150.0% during the 4th quarter. Vestal Point Capital LP now owns 13,750,000 shares of the company’s stock valued at $75,625,000 after acquiring an additional 8,250,000 shares during the last quarter. Finally, Virtus Investment Advisers LLC grew its stake in shares of Taysha Gene Therapies by 7.0% in the fourth quarter. Virtus Investment Advisers LLC now owns 45,946 shares of the company’s stock worth $253,000 after acquiring an additional 3,008 shares during the period. 77.70% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of equities analysts have issued reports on the company. UBS Group set a $11.00 price objective on Taysha Gene Therapies in a report on Thursday, December 4th. Chardan Capital reaffirmed a “buy” rating and issued a $12.00 target price on shares of Taysha Gene Therapies in a research report on Tuesday, January 6th. Raymond James Financial reiterated a “strong-buy” rating and issued a $13.00 price target on shares of Taysha Gene Therapies in a research note on Tuesday, January 6th. Wall Street Zen cut shares of Taysha Gene Therapies from a “hold” rating to a “sell” rating in a research report on Saturday, January 3rd. Finally, Needham & Company LLC restated a “buy” rating and issued a $10.00 price objective on shares of Taysha Gene Therapies in a report on Tuesday, March 3rd. One investment analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Taysha Gene Therapies has a consensus rating of “Moderate Buy” and a consensus target price of $10.91.

About Taysha Gene Therapies

Taysha Gene Therapies, Inc (NASDAQ: TSHA) is a clinical-stage biotechnology company focused on developing gene therapies for rare monogenic diseases of the central nervous system. Using a proprietary adeno-associated viral (AAV) vector platform, the company engineers novel capsids and regulatory elements to optimize delivery and expression of therapeutic genes. Its pipeline features lead programs such as TSHA-102 for GM2 gangliosidoses (Tay–Sachs and Sandhoff diseases), TSHA-101 for GM1 gangliosidosis and TSHA-103 for aromatic l-amino acid decarboxylase (AADC) deficiency, alongside earlier-stage candidates targeting other life-threatening pediatric CNS disorders.

Founded in 2019 and headquartered in Dallas, Texas, Taysha Gene Therapies completed its initial public offering in May 2021.